MedTrace Logo

NAC for Attenuation of COVID-19 Symptomatology

NCT05074121 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-08-07

No results posted yet for this study

Summary

The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.

Conditions

  • Covid19
  • COVID-19 Pneumonia
  • COVID-19 Respiratory Infection
  • COVID-19 Lower Respiratory Infection
  • SARS-CoV2 Infection
  • SARS-CoV-2 Acute Respiratory Disease
  • SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
  • Oxidative Stress

Interventions

DRUG

N-acetylcysteine

N-acetylcysteine

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • The Thoracic Foundation

    collaborator UNKNOWN

  • Alturix

    collaborator UNKNOWN

  • Cambridge Health Alliance

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2024-12-31
Completion
2025-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05074121 on ClinicalTrials.gov